Colorectal cancer|https://phgkb.cdc.gov/GAPPKB/phgHome.do|Colorectal cancer

https://phgkb.cdc.gov/GAPPKB/phgHome.do

From Tier Table Database

CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.

---

Disease/Disorder	Test to be Assessed	Intended Use	Tier Classified	Detail
Metastatic colorectal cancer	NRAS or PIK3CA mutation analysis and/or testing for loss of PTEN or AKT protein expression	Pharmacogenomic for anti-EGFR therapy	Tier 3
Dukes’ C colon cancer, metastatic colorectal cancer, metastatic breast cancer	DPD testing	Pharmacogenomic for 5-FU (capecitabine)	Tier 2
Colorectal cancer in patient with relatives (two or more first- or second-degree) with Lynch syndrome related cancer at any age	Testing for Lynch syndrome	Diagnostic, screening	Tier 2
Colorectal cancer in patient with relative (one or more first-degree) with Lynch syndrome related cancer that was diagnosed under age 50 years	Testing for Lynch syndrome	Diagnostic, screening	Tier 2
MSI-H histology in colorectal cancer patients younger than 60 years	Testing for Lynch syndrome	Diagnostic, screening	Tier 2

more